SLC31A1 and ovarian cancer: Recent findings on copper-controlled CTR1 expression have initiated a phase I clinical trial assessing the usefulness of therapy with a copper chelator (trientine) as an enhancer in advanced ovarian cancer chemotherapy based on carboplatin (Fu et al. 2012).